%0 Journal Article
%T Effect of Simvastatin on the Pharmacodynamic Activity of Repaglinide in Rats/Rabbits
%J International Journal of Diabetes Research
%@ 2163-1646
%D 2012
%I 
%R 10.5923/j.diabetes.20120104.02
%X Dyslipidemia is common in patients with type 2 diabetes. Statins are used as the first choice in treatment of diabetic dyslipidemia. Simvastatin, an HMG-CoA reductase inhibitor, is widely used in the treatment of hypercholesterolemia. Repaglinide is a short-acting, oral, insulin secretagogue that is used in the treatment of type 2 diabetes mellitus. Both the category of drugs undergo extensive metabolism with cytochrome P450 enzyme system. This may lead to drug-drug interaction problems with altered repaglinide activity which is unwanted. Simvastatin/repaglinide/simvastatin+repaglinide were administered orally to normal, diabetic rats, and to normal rabbits. Blood samples were collected at different time intervals and were analyzed for blood glucose by GOD¨CPOD method using commercial glucose kits and repaglinide estimation in plasma by HPLC method. Diabetes was induced by alloxan 100 mg/kg body weight administered by I.P route. Simvastatin + repaglinide produced hypoglycemic activity in a dose dependant manner in normal and diabetic condition. In the presence of simvastatin, repaglinide blood glucose lowering activity was not increased significantly (P<0.05) compared with repaglinide matching control. The present study concludes co-administration of simvastatin was not improved repaglinide responses significantly in animal models.
%K Repaglinide
%K Simvastatin
%K Diabetic Dyslipidaemia
%K Rats
%K Rabbits
%U http://article.sapub.org/10.5923.j.diabetes.20120104.02.html